DelveInsight’s “DHODH Inhibitor Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the DHODH Inhibitor pipeline landscape. It covers the DHODH Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the DHODH Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the DHODH Inhibitor Pipeline? Click here to explore the therapies and trials making headlines @ DHODH Inhibitor Pipeline Outlook Report

Key Takeaways from the DHODH Inhibitor Pipeline Report

• DelveInsight’s DHODH Inhibitor Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for DHODH Inhibitor treatment.
• The leading DHODH Inhibitor Companies, such as Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture, and others.
• Promising DHODH Inhibitor Therapies such as RP7214, IMU-838, PTC 299, and others.

Want to know which companies are leading innovation in DHODH Inhibitor? Dive into the full pipeline insights @ DHODH Inhibitor Clinical Trials Assessment

The DHODH Inhibitor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The DHODH Inhibitor Pipeline Report also highlights the unmet needs with respect to the DHODH Inhibitor.

DHODH Inhibitor Overview

Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as Acute Myeloid Leukemia, Rheumatoid Arthritis, and Multiple Sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID-19 Treatment using DHODH inhibitors.

DHODH Inhibitor Emerging Drugs Profile

• IMU-838: Immunic

IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.

• PTC 299: PTC Therapeutics

Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.

If you’re tracking ongoing DHODH Inhibitor Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ DHODH Inhibitor Treatment Drugs

The DHODH Inhibitor Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of DHODH Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for DHODH Inhibitor Treatment.
• DHODH Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• DHODH Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the DHODH Inhibitor market.

DHODH Inhibitor Companies

Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.

DHODH Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

DHODH Inhibitor Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

From emerging drug candidates to competitive intelligence, the DHODH Inhibitor Pipeline Report covers it all – check it out now @ DHODH Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the DHODH Inhibitor Pipeline Report

• Coverage- Global
• DHODH Inhibitor Companies- Sanofi, Immunic, PTC Therapeutics, Clear Creek Bio, EyeGate Pharma, ASLAN Pharmaceuticals, Medicines for Malaria Venture and others.
• DHODH Inhibitor Therapies- RP7214, IMU-838, PTC 299, and others.
• DHODH Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• DHODH Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the DHODH Inhibitor Treatment landscape in this detailed analysis @ DHODH Inhibitor Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dihydroorotate Dehydrogenase (DHODH) Inhibitor – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug name: Company name
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II/III)
13. IMU-838: Immunic
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I/II)
16. PP 001: EyeGate Pharma
17. Drug profiles in the detailed report…..
18. Pre-clinical and Discovery Stage Products
19. MMV-1793609: Medicines for Malaria Venture
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
23. Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products
24. Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs
25. Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers
26. Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion
27. Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views
28. Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dihydroorotate-dehydrogenase-dhodh-inhibitor-pipeline-insight